ChiCTR2000039837 版本V1.0 版本创建时间2021/02/19 20:16:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039837 

最近更新日期:

Date of Last Refreshed on:

2020-11-12 01:01:52 

注册时间:

Date of Registration:

2020-11-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

人呼出气幽门螺杆菌无创检测新技术临床诊断试验

Public title:

Diagnostic clinical study of a novel noninvasive detection of helicobacter pylori in human exhalation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于量子级联激光检测人呼出气幽门螺杆菌C13临床诊断试验

Scientific title:

Diagnostic clinical study of quantum cascade lasers(QCL) detection of C13 for helicobacter pylori in human exhalation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡彬 

研究负责人:

李强 

Applicant:

Hu Bin 

Study leader:

Li Qiang 

申请注册联系人电话:

Applicant telephone:

18081006537

研究负责人电话:

Study leader's telephone:

18908178887

申请注册联系人传真 :

Applicant Fax:

02885420116

研究负责人传真:

Study leader's fax:

02885420116

申请注册联系人电子邮件:

Applicant E-mail:

hubin9251102@yahoo.com

研究负责人电子邮件:

Study leader's E-mail:

liqiang1907@vip.sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.sichuancancer.org/

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.sichuancancer.org/

申请注册联系人通讯地址:

四川省成都市人民南路四段55号

研究负责人通讯地址:

四川省成都市人民南路四段55号

Applicant address:

No.55, Sect.4 Renmin Nan Road | Chengdu, Sichuan Province

Study leader's address:

No.55, Sect.4 Renmin Nan Road | Chengdu, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川省肿瘤医院

Applicant's institution:

Sichuan Cancer Hospital and Institute

研究负责人所在单位:

四川省肿瘤医院

Affiliation of the Leader:

Sichuan Cancer Hospital and Institute

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SCCHEC-02-2020-023

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川省肿瘤医院伦理委员会

Name of the ethic committee:

Ethics Committee of Sichuan Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-31 00:00:00

伦理委员会联系人:

周维嘉

Contact Name of the ethic committee:

Zhou Weijia

伦理委员会联系地址:

四川省成都市人民南路四段55号

Contact Address of the ethic committee:

No.55, Sect.4 Renmin Nan Road | Chengdu, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川省肿瘤医院

Primary sponsor:

Sichuan Cancer Hospital and Institute

研究实施负责(组长)单位地址:

四川省成都市人民南路四段55号

Primary sponsor's address:

No.55, Sect.4 Renmin Nan Road | Chengdu, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川省肿瘤医院

具体地址:

人民南路四段55号

Institution
hospital:

Sichuan Cancer Hospital and Institute

Address:

55 Fourth Section of Renmin Road South

经费或物资来源:

四川省科技厅重大研发项目(2019YFG0517)

Source(s) of funding:

project of Sichuan Science and Technology Department(2019YFG0517)

Target disease:

Gastritis, Upper gastrointestinal ulcer

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

基于量子级联激光(QCL)检测装置,无创快速检测人体胃部幽门螺旋杆菌的碳 13-尿素呼气试验(C13-UBT)。实现对于人体呼出 CO2 中的 13C/12C 同位素比例进行精确检测,并开展相关临床检测验证。  

Objectives of Study:

Based on the quantum cascade laser (QCL) detection device, the carbon 13-urea breath test (c13-ubt) was used to rapidly detect helicobacter pylori in human stomach. To realize accurate detection of 13C/12C isotope ratio in CO2 from human exhalation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄18-70岁,不限性别,拟行C13-UBT检测的受试者。

Inclusion criteria

Subjects aged 18-70 years, regardless of gender, who plan to undergo C13-UBT test.

排除标准:

近3个月患心肌梗死、脑卒中、休克者;近4周严重心功能不全、严重心律失常、不稳定性心绞痛,严重高血压及高血压危象患者(收缩压>200 mmHg、舒张压>100 mmHg),或胸腹主动脉瘤患者;气胸及气胸愈合后1月内患者、严重肺大泡者、严重低氧血症及严重呼吸衰竭患者;近4周大咯血;癫痫发作需要药物治疗;肺功能检查当天,内窥镜检查及活检后患者;严重甲状腺功能亢进;免疫力低下易受感染者;体弱无力或重症肌无力患者;无法配合者:如剧烈咳嗽、偏瘫、面瘫、脑瘫、以及智障患者、失聪患者;对PE材料有过敏史者;妊娠或哺乳期妇女;研究者认为不适宜参加本临床试验者

Exclusion criteria:

Myocardial infarction, stroke and shock in the last 3 months;Patients with severe cardiac insufficiency, severe arrhythmia, unstable angina, severe hypertension and hypertensive crisis (systolic blood pressure >200 mmHg, diastolic blood pressure >100 mmHg) in the last 4 weeks, or patients with thoracic and abdominal aortic aneurysm;Patients with pneumothorax and pneumothorax within 1 month after pneumothorax healing, patients with severe pulmonary bullae, severe hypoxemia and severe respiratory failure;Hemoptysis in recent 4 weeks;Seizures require medical treatment;On the day of pulmonary function examination, after endoscopy and biopsy;Severe hyperthyroidism;Vulnerable to infection due to low immunity;Patients with weak or myasthenia gravis;Unable to cooperate: such as severe cough, hemiplegia, facial palsy, cerebral palsy, as well as mentally disabled patients, deaf patients;Allergic history to PE materials;Pregnant or lactating women;The investigator did not consider it appropriate to participate in this clinical trial

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

碳 13-尿素呼气试验的检测结果

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Results of carbon 13- urea breath test

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

量子级联激光检测装置(QCL)检测人体胃部幽门螺旋杆菌的检测结果,设备安全性,稳定性。

Index test:

Quantum cascade laser detection device (QCL) detects H. pylori in human stomach, testing the safety and reliabilty.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

幽门螺杆菌感染者

例数:

Sample size:

200

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Helicobacter pylori infection cases

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

非幽门螺杆菌感染胃炎病例

例数:

Sample size:

100

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Non-helicobacter pylori infection in gastritis cases

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省肿瘤医院 

单位级别:

省级 

Institution
hospital:

Sichuan Cancer Hospital and Institute

Level of the institution:

Province class

测量指标:

Outcomes:

指标中文名:

碳13含量

指标类型:

主要指标

Outcome:

C13 content

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

人呼出气

组织:

Sample Name:

human exhalation

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心,网址http://www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry, http://www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

我们将应用四川省肿瘤医院REDCap平台进行数据采集和管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will use REDCap established in Sichuan Cancer Hospital for data collection and management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-11-12 01:01:52